Pharming announces completion of financing for RUCONEST® North American Rights Acquisition

Wednesday, December 7, 2016

Pharming Group N.V.announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104 million before costs. The financing will be used to pay the upfront amount of US$60 million (approximately €56.1 million) for completion of the transaction with subsidiaries of Valeant Pharmaceuticals International, Inc.  signed on 9 August 2016 for Pharming to acquire the commercialization rights to its own high quality Heritary Angioedema therapy RUCONEST® in North America. 

Find out more about drug development at Leiden Bio Science Park.